Eli Lilly Stock - Analyst debate after powerful run
21.06.2026 - 07:21:57 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 05:20 UTC. Details in the imprint.
Eli Lilly & Co. (US5324571083) has become one of the most discussed large-cap pharma names after a double-digit 12-month share price gain. Recent analyst commentary highlights both confidence in the company’s growth engines and rising concern over valuation, according to a Simply Wall St analysis on Yahoo Finance.
All news and analysis on Eli Lilly stock
Key figures, background and recent analyst views on Eli Lilly stock are compiled in our dedicated topic section and on the company’s own investor relations pages.
What recent numbers signal
In a recent valuation-focused piece carried by Yahoo Finance, Eli Lilly’s stock was cited with a latest close around $1,098.57, marking a 45.1% gain over the past year and about 5.5% over the last month, while slipping roughly 3.0% in the past week. Yahoo Finance/Simply Wall St analysis
The same analysis notes that Eli Lilly trades on a trailing price-earnings ratio near 38.8, compared with roughly 14.8 for the broader pharmaceuticals industry and about 23.0 for a peer group, underlining how far the stock’s valuation has stretched versus sector averages. Yahoo Finance/Simply Wall St analysis
Sunday background on consensus
According to aggregated analyst data on TradingKey, Eli Lilly currently carries an overall rating of "Buy" with an average price target of about $1,210.97, implying upside potential from recent trading levels despite the already strong advance. TradingKey consensus snapshot
The same overview lists a market capitalization near $1.03 trillion, underscoring how Eli Lilly has shifted into the very top tier of global healthcare companies by equity value, ahead of many long-established Big Pharma peers. TradingKey consensus snapshot
The product behind the stock
Eli Lilly generates the bulk of its revenue from branded prescription medicines, notably blockbuster diabetes and obesity treatment Mounjaro and its related weight-loss brand Zepbound, alongside oncology and immunology therapies that broaden the company’s growth base.
Where the stock trades today
The shares of Eli Lilly & Co. (US5324571083) trade on the New York Stock Exchange at approximately $1,099.48 as of 06/18/2026, 16:00 ET, according to recent market data.
Key facts on Eli Lilly stock
- Company: Eli Lilly and Company
- ISIN: US5324571083
- WKN: 858560
- Ticker: LLY
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): 1,099.48 USD
- Market cap: 1.03 trillion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
